Altimmune, Inc. reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was USD 0.005 million compared to USD 0.006 million a year ago. Sales was USD 0.005 million compared to USD 0.006 million a year ago. Net loss was USD 24.64 million compared to USD 16.06 million a year ago. Net loss was USD 24.64 million compared to USD 16.06 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.32 a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.32 a year ago.
For the six months, sales was USD 0.01 million compared to USD 0.027 million a year ago. Net loss was USD 49.03 million compared to USD 36.14 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 0.72 a year ago.